Kazia Therapeutics Limited is classed by the SEC under Pharmaceutical Preparations (industry code 2834). In its latest annual figures on file, for the fiscal year ended 2025-06-30, it reported revenue of AUD 42 thousand and a loss of AUD 21 million (its filed statements).
Pre-revenue companyPharmaceutical Preparationsfilings since 20027 of 9 filed, 2 estimated
Three tenses, nine metrics. Unseen metrics stay unseen; the grade never fakes a number. Proxy era: provisional values, marked. Weighed as a pre-revenue company: no meaningful revenue on file yet (industry code 2834), so it is read as a pre-revenue company; the filing read can change it. All three tenses have at least two readings, so the archetype blend applies as printed.
The grade, in three tenses
Headline 2.9 out of ten, 7 of 9 metrics filed and 2 estimated: past 2.5 out of ten, present 2.6 out of ten, future 3.6 out of ten. The past asks what it actually did, the present what it is doing right now, the future what it is set up to do next.
The nine metrics
Surviving crises (past): 5.6 out of ten. 2 warning events since 2017; the latest 2025-10-31. 56th percentile among 497 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Track record (past): 1.4 out of ten. -22.3% a year over 6 filed years; profitable in 0 of 9. 14th percentile among 324 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Shareholder treatment (past): 1.9 out of ten. CrossAssetData estimate 1.9/10, confidence 35 of 100 (one part). 19th percentile among 463 sector filers. A CrossAssetData estimate, not a filed reading: one part, confidence 35 of 100; a filing that carries the missing parts replaces this estimate with the filed reading.
Financial health (present): 1.3 out of ten. Leverage 237%: owes 237¢ per asset dollar. 13th percentile among 472 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Industry position (present): 1.4 out of ten. bottom 14% of 314 in its family; net margin -49290.5%. 14th percentile among 314 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Leadership (present): 5.0 out of ten. CrossAssetData estimate 5.0/10, confidence 20 of 100 (family median). 50th percentile among 371 sector filers. A CrossAssetData estimate, not a filed reading: family median, confidence 20 of 100; its next annual report on file with the inputs replaces this estimate with the filed reading.
Room to expand (future): 5.9 out of ten. top 41% of 272 in its family for room to expand. 59th percentile among 272 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Growth drivers (future): 2.4 out of ten. bottom 24% of 307 in its family for growth drivers. 24th percentile among 307 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Expectations vs reality (future): 2.5 out of ten. bottom 24% of 234 in its family for expectations against reality. 24th percentile among 234 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
The filing record
Newest annual report: Form 20-F filed 2025-11-07 for the period ended 2025-06-30 (on EDGAR). Newest filing: Form SCHEDULE 13G/A, 2026-10-02. Filings on record since 2002. Read from EDGAR 2026-10-12.
Who runs it
Friend, John E. II (Chief Executive Officer); Levine, James E. (Chief Financial Officer); Rao, Sudha (Chief Scientific Officer); Bonacorda, Jeffrey (VP, Finance and Controller); Cain, David (Director, CMC); Simpson, Jeremy (Program Director); Apple, Robert F (director); Coffey, Steven R. S. (director); Davidson, Ebru (director). 9 officers and directors have filed their own trades in the last fifteen months, names and titles as filed with the SEC, through 2026-09-30.
Every stock is a company. We grade the company behind the stock. CrossAssetData is a company research product: no investment advice, no price targets, no price predictions; every claim carries its source, and unseen means unseen. The full file draws when the page's script runs: the essentials, the balance sheet, the estimators, the trend, and every filing of the last ten years.